RNS Number : 4870N
Shield Therapeutics PLC
02 January 2026

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Block Listing 6 Monthly Return

Name of applicant:		SHIELD THERAPEUTICS PLC		
Name of scheme:		Shield Therapeutics Retention Share Plan		
Period of return:	From:	01 July 2025	To:	31 December 2025
Balance of unallotted securities under scheme(s) from previous return:		39,794		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL		
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		39,794		

Name of applicant:		SHIELD THERAPEUTICS PLC		
Name of scheme:		Shield Therapeutics plc 2016 Company Share Option Plan		
Period of return:	From:	01 July 2025	To:	31 December 2025
Balance of unallotted securities under scheme(s) from previous return:		341,020		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL		
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		341,020		

Name of applicant:		SHIELD THERAPEUTICS PLC		
Name of scheme:		The Shield Therapeutics plc 2016 Long Term Incentive Plan		
Period of return:	From:	01 July 2025	To:	31 December 2025
Balance of unallotted securities under scheme(s) from previous return:		24,273		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL		
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		24,273		

Name of applicant:		SHIELD THERAPEUTICS PLC		
Name of scheme:		Shield Therapeutics Retention and Performance Share Plan		
Period of return:	From:	01 July 2025	To:	31 December 2025

Balance of unallotted securities under scheme(s) from previous return:	2,870,838
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	15,000,000
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	6,137,791
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	11,733,071

Name of contact:	Lucy Huntington-Bailey
Telephone number of contact:	+44 (0) 191 511 8500

For further information please contact:

Shield Therapeutics plc www.shieldtherapeutics.com
Anders Lundstrom, CEO
Santosh Shanbhag, CFO
Lucy Huntington-Bailey, Company Secretary
+44 (0) 191 511 8500
info@shieldtx.com

Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Christoper Golden +44 (0)20 7418 8900

Joint Broker
Cavendish Ltd
Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward +44 (0)20 7220 0500

About Iron Deficiency and ACCRUFeR®/FeRACCRU®
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.

About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU® is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.
ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information

contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLREAFFAEESKEFA